Milk Thistle (Silybum marianum) is a flowering plant whose seeds contain a complex of flavonolignans collectively known as silymarin. The most active component is silybin (silibinin), which comprises 50-70% of the silymarin complex. Milk Thistle has been used for liver support for over 2,000 years and is the most popular liver supplement worldwide. For steroid users, it provides a baseline level of hepatoprotection through antioxidant, anti-inflammatory, and hepatocyte-regenerative mechanisms. However, it is important to understand that Milk Thistle alone is NOT sufficient liver protection for oral steroid cycles — it should be used as part of a comprehensive stack with NAC and TUDCA rather than as a standalone protectant.
Notes
Milk Thistle has been used medicinally since at least the first century AD (described by Pliny the Elder). Modern pharmacological research began in the 1960s when silymarin was first isolated and characterized. Despite thousands of studies, clinical evidence for dramatic hepatoprotective effects in humans is mixed — the benefit is most clear in toxic exposures (Amanita mushroom poisoning, drug-induced liver injury) and chronic hepatitis. For steroid users, it provides meaningful but modest protection that is best used as part of a multi-supplement liver support protocol rather than as a standalone solution.
Silymarin's hepatoprotective effects operate through multiple mechanisms: (1) Antioxidant: Silybin directly scavenges free radicals (ROS) and increases intracellular glutathione levels by 35% through stimulation of glutathione synthesis — complementary to NAC's mechanism. (2) Anti-inflammatory: Inhibits NF-kB pathway, reduces TNF-alpha, IL-1beta, and IL-6 production in hepatocytes and Kupffer cells. (3) Membrane stabilization: Silybin integrates into hepatocyte cell membranes, reducing permeability and preventing toxin entry. (4) Protein synthesis stimulation: Stimulates RNA polymerase I in hepatocyte nuclei, increasing ribosomal protein synthesis — this accelerates hepatocyte regeneration and repair. (5) Anti-fibrotic: Inhibits hepatic stellate cell activation and collagen deposition, reducing fibrosis progression. (6) Mild choleretic: Promotes bile flow, though far less potently than TUDCA.
Standard silymarin has low oral bioavailability (20-50%) due to poor water solubility and extensive first-pass metabolism. Silybin phytosome (phosphatidylcholine complex) increases bioavailability by 4-10 fold. Peak plasma levels in 2-4 hours (standard) or 1-2 hours (phytosome). Protein binding approximately 80%. Metabolized by Phase II conjugation (glucuronidation and sulfation) in the liver. Half-life of 6-8 hours. Undergoes enterohepatic recycling. Excreted primarily in bile and feces (~80%) with minor renal excretion (~5%).
Typical Dose
General liver support: 200-400mg silymarin daily. On-cycle support (alongside NAC/TUDCA): 400-600mg silymarin daily. Post-cycle liver recovery: 400mg silymarin daily for 4-8 weeks. Phytosome formulation (Siliphos): 160-320mg silybin-phosphatidylcholine complex daily.
Frequency
Split into 2-3 doses daily with meals for best absorption. Phytosome formulations can be dosed once or twice daily.
Administration
Oral capsule or extract. Standardized extracts (70-80% silymarin) are preferred over raw herb. Take with meals containing fat for improved absorption. Phosphatidylcholine-complexed formulations (Siliphos/Silybin Phytosome) have dramatically better bioavailability.
Half-Life
6-8 hours for silybin (primary active compound)
Contraindications